| [1] |
Zhang L, Zhao MH, Zuo L, et al. China Kidney Disease Network(CK-NET) 2016 annual data report [J]. Kidney Int Suppl (2011), 2020, 10(2): e97-e185.
|
| [2] |
李娟，卢婉君，龚书豪，等. 慢性肾衰竭腹膜透析患者微炎症状态的研究进展[J]. 南昌大学学报(医学版), 2021, 61(3): 80-83.
|
| [3] |
Lambie M, Bonomini M, Davies SJ, et al. Insulin resistance in cardiovascular disease, uremia, and peritoneal dialysis [J]. Trends Endocrinol Metab, 2021, 32(9): 721-730.
|
| [4] |
Packer M. Potentiation of insulin signaling contributes to heart failure in type 2 diabetes: a hypothesis supported by both mechanistic studies and clinical trials [J]. JACC Basic Transl Sci, 2018, 3(3): 415-419.
|
| [5] |
史春夏，李妍，史亚男，等. 自动化腹膜透析治疗持续不卧床腹膜透析并发心力衰竭患者的临床观察[J]. 中国血液净化，2020, 19(2): 99-102.
|
| [6] |
靳敬伟，张玉乾，刘梅，等. 百令胶囊联合左卡尼汀对维持性腹膜透析患者肾功能、微炎症状态、营养状况及生活质量的影响分析[J]. 解放军医药杂志，2021, 33(6): 97-100, 109.
|
| [7] |
朱贺. 不同剂量非布司他联合依托考昔，别嘌呤醇对高尿酸血症合并痛风患者的疗效比较[J]. 中国医学创新，2021, 18(34): 52-55.
|
| [8] |
Nochaiwong S, Ruengorn C, Mongkhon P, et al. Effects of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on all-cause mortality, cardiovascular death, and cardiovascular events among peritoneal dialysis patients: a protocol for systematic review [J]. Medicine (Baltimore), 2020, 99(17): e19767.
|
| [9] |
Jegatheesan D, Cho Y, Johnson DW. Clinical studies of interventions to mitigate cardiovascular risk in peritoneal dialysis patients [J]. Semin Nephrol, 2018, 38(3): 277-290.
|
| [10] |
Zoccali C, Ortiz A, Blumbyte IA, et al. Neuropeptide Y as a risk factor for cardiorenal disease and cognitive dysfunction in chronic kidney disease: translational opportunities and challenges [J]. Nephrol Dial Transplant, 2021, 37(Suppl 2): ii14-ii23.
|
| [11] |
Eikelboom J, Floege J, Thadhani R, et al. Anticoagulation in patients with kidney failure on dialysis: factor XI as a therapeutic target [J]. Kidney Int, 2021, 100(6): 1199-1207.
|
| [12] |
Merino RA, Araujo R, Pereira L, et al. Vascular calcification and the gut and blood microbiome in chronic kidney disease patients on peritoneal dialysis: a pilot study [J]. Biomolecules, 2022, 12(7): 867.
|
| [13] |
Ridker PM, Devalaraja M, Baeres F, et al. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial [J]. Lancet, 2021, 397(10289): 2060-2069.
|
| [14] |
Li PK, Chow KM, Cho Y, et al. ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment [J]. Perit Dial Int, 2022, 42(2): 110-153.
|
| [15] |
Chang TI, Kim HW, Park JT, et al. Early catheter removal improves patient survival in peritoneal dialysis patients with fungal peritonitis: results of ninety-four episodes of fungal peritonitis at a single center [J]. Perit Dial Int, 2011, 31(1): 60-66.
|
| [16] |
Miles R, Hawley CM, Mcdonald SP, et al. Predictors and outcomes of fungal peritonitis in peritoneal dialysis patients [J]. Kidney Int, 2009, 76(6): 622-628.
|
| [17] |
Zhong HJ, Lin D, Lu ZY, et al. Use of gastric-acid suppressants may be a risk factor for enteric peritonitis in patients undergoing peritoneal dialysis: a meta-analysis [J]. J Clin Pharm Ther, 2019, 44(2): 209-215.
|
| [18] |
庄永泽，张路英，王烈，等. 延迟拔管的腹膜透析相关性腹膜炎救治新技术的建立与应用[J]. 中国中西医结合肾病杂志，2020, 21(11): 951-954.
|
| [19] |
姜鸿，吴亚琴，谭一香. 抗炎联合低浓度碘伏封管治疗难治性腹膜炎的初步探索[J]. 中国血液净化，2018, 17(6): 374-377.
|
| [20] |
Barrios R, Nadal ML, Vion VB, et al. Relapsing peritonitis and taurolidine peritoneal catheter lock: one center experience [J]. J Vasc Access, 2021, 22(2): 261-265.
|
| [21] |
Klimek K, Fosalba NA, Lopez M, et al. Taurolidine as adjuvant treatment of relapsing peritonitis in peritoneal dialysis patients [J]. Nefrologia (Engl Ed), 2020, 40(2): 197-201.
|
| [22] |
Mujais S. Evaluation and management of ultrafiltration problems in PD [J]. Perit Dial Int, 2000, 20(4): 5-21.
|
| [23] |
Ambruso SL, Teitelbaum I. Prevention of peritoneal dialysis drop-out [J]. Adv Perit Dial, 2018, 34(2018): 19-23.
|
| [24] |
Vrtovsnik F, Verger C, Biesen WV, et al. The impact of volume overload on technique failure in incident peritoneal dialysis patients [J]. Clin Kidney J, 2019, 14(2): 570-577.
|
| [25] |
Terri M, Trionfetti F, Montaldo C, et al. Mechanisms of peritoneal fibrosis: focus on immune cells-peritoneal stroma interactions [J]. Front Immunol, 2021, 12: 607204.
|
| [26] |
Krediet R. Acquired decline in ultrafiltration in peritoneal dialysis: the role of glucose [J]. J Am Soc Nephrol, 2021, 32(10): 2408-2415.
|
| [27] |
Teitelbaum I. Ultrafiltration failure in peritoneal dialysis: a pathophysiologic approach [J]. Blood Purif, 2015, 39(3): 70-73.
|
| [28] |
Song J, Yang X, Yan LJ. Role of pseudohypoxia in the pathogenesis of type 2 diabetes [J]. Hypoxia, 2019, 7(6): 33-40.
|
| [29] |
Jaques DA, Davenport A. Determinants of volume status in peritoneal dialysis: a longitudinal study [J]. Nephrology (Carlton), 2020, 25(10): 785-791.
|
| [30] |
廖梦，陈思洁，汤日宁，等. 内皮-间充质转分化在腹膜透析相关腹膜纤维化中的研究进展[J]. 临床肾脏病杂志，2021, 21(10): 848-855.
|
| [31] |
Si M, Wang Q, Li Y, et al. Inhibition of hyperglycolysis in mesothelial cells prevents peritoneal fibrosis [J]. Sci Transl Med, 2019, 11(495): eaav5341.
|
| [32] |
Li YC, Sung PH, Yang YH, et al. Dipeptidyl peptidase 4 promotes peritoneal fibrosis and its inhibitions prevent failure of peritoneal dialysis [J]. Commun Biol, 2021, 4(1): 144.
|
| [33] |
Kim YC, Kim KH, Lee S, et al. ST2 blockade mitigates peritoneal fibrosis induced by TGF-β and high glucose [J]. J Cell Mol Med, 2019, 23(10): 6872-6884.
|
| [34] |
Helmke A, Nordlohne J, Balzer MS, et al. CX3CL1-CX3CR1 interaction mediates macrophage-mesothelial cross talk and promotes peritoneal fibrosis [J]. Kidney Int, 2019, 95(6): 1405-1417.
|
| [35] |
Duan Z, Yao J, Duan N, et al. Sulodexide prevents peritoneal fibrosis by downregulating the expression of TGF-β1 and its signaling pathway molecules [J]. Evid Based Complement Alternat Med, 2021, 2021: 2052787.
|
| [36] |
Guo Y, Wang L, Gou R, et al. Ameliorative role of SIRT1 in peritoneal fibrosis: an in vivo and in vitro study [J]. Cell Biosci, 2021, 11(1): 79.
|
| [37] |
Shi Y, Hu Y, Wang Y, et al. Blockade of autophagy prevents the development and progression of peritoneal fibrosis [J]. Front Pharmacol, 2021, 12: 724141.
|
| [38] |
Liu Y, Zhang L, Lin A, et al. Impact of break-in period on the short-term outcomes of patients started on peritoneal dialysis [J]. Perit Dial Int, 2014, 34(1): 49-56.
|
| [39] |
孔德亮，李娟，赖学莉，等. 腹膜透析管安置术后患者发生大网膜包裹的危险因素分析[J]. 上海医学，2017, 40(1): 31-35.
|
| [40] |
Dufek S, Holtta T, Fischbach M, et al. Pleuro-peritoneal or pericardio-peritoneal leak in children on chronic peritoneal dialysis-a survey from the European paediatric dialysis working group [J]. Pediatr Nephrol, 2015, 30(11): 2021-2027.
|